In vivo 1H and 31P MRS were used to monitor the effects of BRAF and MEK inhibitors therapy in two metabolically different melanoma xenograft models. Our approach is to combine BRAF inhibitor with MEK inhibitor in melanoma xenograft models. Combination of BRAF and MEK inhibitors has been shown to be more effective than the use of either drug alone. Differences in relative levels of glycolysis between two melanoma xenograft models may produce differential therapeutic responses to BRAF and MEK inhibitors . In melanoma, metabolic changes in response to targeted kinase inhibitor therapy occur rapidly and are related to subsequent tumor response.
This abstract and the presentation materials are available to members only; a login is required.